tbuckley/cabot-search huggingface dataset:
AB0047 High Soluble IL-7 Receptor Expression in Sjögren's Syndrome Identifies Patients with Increased Immunopathology and Dryness
Authors: M.R. Hillen, S.L. Blokland, A.P. Risselada, A. Bikker, B.R. Lauwerys, A.A. Kruize, T.R. Radstake, J.A. van Roon
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Increased expression of interleukin (IL)-7 and its receptor plays a critical role in immunopathology of primary Sjögren9s syndrome (pSS). The IL-7/IL-7R axis is involved in formation of (ectopic) lymphoid structures, which is a predictor for lymphoma development in pSS. IL-7 activity is potentiated by the soluble form of its receptor (sIL-7R), which is produced in inflamed tissues by activated stromal cells. Thus, sIL-7R may serve as a biomarker for IL-7-driven activation and lymphoid neogenesis. <h3>Objectives</h3> We studied the expression of sIL-7R in pSS in relation to markers of inflammation and saliva production. <h3>Methods</h3> 95 pSS patients were diagnosed according to the 2002 criteria. sIL-7R concentration was measured in serum of 68 pSS patients using ELISA and compared to 51 healthy individuals (HC). Labial salivary gland (LSG) biopsy tissues were taken from 27 patients and were incubated in sterile saline for 1 hour at room temperature. sIL-7R was measured using multi-cytokine analysis by Luminex and compared to 24 non-Sjögren9s sicca (nSS) patients. <h3>Results</h3> Serum levels of sIL-7R were significantly higher in pSS patients compared to healthy controls (median [range]: 610 [52–2201] vs. 294 [58–821] pMol/mL, p=0.0001). pSS patients with sIL-7R levels above those of HC, defined as sIL-7Rhigh, showed markedly increased ESR, serum IgG and lymphocytic focus scores compared to the other pSS patients. Furthermore, sIL-7Rhigh patients had significantly decreased salivary output, as measured by stimulated whole saliva and unstimulated whole saliva (median [range]: 0.2 [0.0–0.9] vs. 1.2 [0.0–4.6] mL/min, p=0.01). In addition, we observed increased sIL-7R production in LSG supernatants from pSS patients compared to nSS. Similar to serum, a sIL-7Rhigh group could be discerned, with higher levels of serum IgG and increased prevalence of ANA, anti-SSA, and anti-SSB autoantibodies (all at least p&lt;0.05). <h3>Conclusions</h3> Thus, sIL-7R is increased in serum and LSG supernatant of pSS patients, in which high sIL-7R levels identifies patients with increased markers of inflammation and decreased salivary output. The sIL-7R increase in pSS LSG supernatants indicates that the increased systemic sIL-7R levels are at least partially mediated by local production. High local production of sIL-7R was related to increased B-cell activity and autoimmunity, in line with the described role of IL-7 in lymphoid neogenesis. <h3>Disclosure of Interest</h3> None declared
Aerosolized pentamidine promising in Pneumocystis therapy, prophylaxis
Authors: B. Merz
Journal: JAMA (1988)

AEROSOL DELIVERY of pentamidine may be the key to effective prophylaxis and therapy for<i>Pneumocystis carinii</i>pneumonia (PCP) in patients with acquired immunodeficiency syndrome (AIDS). According to early studies, not only does the aerosolized form of the drug appear to eradicate and prevent PCP, it does so without many of the serious side effects associated with parenterally administered pentamidine. The results have prompted two companies, LyphoMed, Inc, Melrose Park, Ill, and Fisons Corporation, Bedford, Mass, to compete for the exclusive rights to market it under the Food and Drug Administration's (FDA) Orphan Drug Act. Both companies are sponsoring extensive clinical trials. LyphoMed, which is backing trials at San Francisco General Hospital, already has exclusive US marketing rights for intravenous and intramuscular pentamidine for the treatment of PCP until 1991. However, that exclusivity applies only to parenteral delivery and an indication for treatment. LyphoMed would also like to have a monopoly
Transactions Medical Association of Georgia.
Authors: L H Orme
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Adults with Standard-Risk Acute Lymphoblastic Leukemia (ALL) the Greatest Benefit Is Achieved from an Allogeneic Transplant in First Complete Remission (CR) and an Autologous Transplant Is Less Effective Than Conventional Consolidation/Maintenance Chemotherapy: Final Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
Authors: Jacob M. Rowe, Georgina Buck, Adele Fielding, Martin S. Tallman, Alan K. Burnett, Raj Chopra, Peter H. Wiernik, Susan M. Richards, Hillard M. Lazarus, Letizia Foroni, Elisabeth Paietta, Mark R. Litzow, David Marks, Jill Durrant, Anthony H. Goldstone
Journal: Blood (2006)
Urine Mutagenicity as an Indicator of Exposure to Dietary Mutagens Formed during Cooking of Foods
Authors: Robert S. U. Baker, Ian Darnton-Hill, Antonio M. Bonin, Andrew Arlauskas, Candida Braithwaite, Michael Wootton, A. Stewart Truswell
Journal: Environmental Health Perspectives (1986)

Studies were undertaken with individuals fed fried bacon meals to determine whether fruit or vegetables, ingested along with bacon, modified uptake and subsequent excretion of bacon mutagen(s). Urinary mutagenic activity was significant in those who had consumed bacon or mixed bacon/vegetable or bacon/fruit meals within the previous 2 to 3 hr period. Although urine activity varied by a factor of 4 among 15 subjects who consumed different meals, there was no evidence from this investigation that fruit or vegetables contributed to the inherent variability in total urinary mutagenic activity. However, some differences in excretion kinetics may be attributable to vegetable or fruit supplements in mixed meals.
Abstracts
Journal: Annals of the Rheumatic Diseases (1964)

The clinical and necropsy records of all adult patients with rheumatic heart disease who had died at the Mount Sinai Hospital, New York, between 1946 and 1959 and in whom fever had been a prominent feature of the terminal illness were studied to determine the relation between the febrile illness and the cardiac condition.Patients in whom rheumatic heart disease was a minor finding, those who had died immediately after admission, and those in whom subacute bacterial endocarditis had been diagnosed before death were excluded.The remaining sixty patients were divided into seven categories according to the cause of fever as revealed at necropsy:(1) Pulmonary infarction was the major finding in 31 patients, nine of whom also had systemic infarction.All but one of these patients were over 40 years old, and 27 had been in congestive failure for up to 5 years before death.(2) Rheumatic activity was responsible for the fever in twelve patients, five of whom were less than 40 and none more than 60 years old.All had died in congestive heart failure, and at necropsy the heart showed evidence of acute rheumatic inflammation, with typical Aschoff nodes in the myocardium in all cases and endocarditis in nine.Active rheumatic fever had been diagnosed before death in only three cases.The serum antistreptolysin-O titre was raised in four of the five cases in which it was determined.(3) Pneumonia was present in six patients, four of whom were over 50.Most had had cough and fever of recent origin, but the clinical and x-ray findings in the chest were not typical of pneumonia.At necropsy bronchopneumonia of one or both lungs was found, but no evidence of pulmonary or systemic infarction.(4) Congestive heart failure was the dominant feature 172 copyright.
PECULIARITIES OF THE SURGICAL DISEASES AND INJURIES OF THE NECK.
Authors: EDMOND SOUCHON
Journal: JAMA (1897)

<h3>PECULIARITIES OF THE SURGICAL DISEASES AND INJURIES OF THE INFRAHYOID REGION.</h3><h3>Congenital malformations.</h3> —It is in the lower part of the region that the orifices of the bronchial congenital fistulæ of the neck are most frequently met, near the head of the clavicle; they may also be met in the thyro-hyoid region. Median fistulæ below the larynx exist but their internal orifice is always pharyngeal, not tracheal. Median thyro-hyoid fistulæ also exist, but they are always secondary, resulting from the rupture of a cyst; there exists only one positively identified case on record. <i>Acquired malformations</i>present no peculiarities. <i>Swellings of the region</i>are mainly due to the various diseases of the thyroid body, which will be especially described further on. <i>Burns and the effects of cold</i>are only peculiar in the possibility of being followed by cicatrices which bind the neck, and chin down to the sterum in a very
Reducing Birth Defect Risk
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tumors of smooth-muscle origin in HIV-infected children
Authors: E. G. Chadwick
Journal: JAMA (1990)

We report the occurrence of multiple leiomyomata and leiomyosarcomata in three children with the acquired immunodeficiency syndrome. The children were infected with human immunodeficiency virus as infants (one perinatally and two through transfusions) and each was profoundly immunosuppressed (absolute CD4 cell count, &lt;75/mm<sup>3</sup>). They experienced multiple infections prior to the diagnosis of neoplasms at ages 4, 5, and 8 years, respectively. The tumors in each case were mainly involving the lungs and gastrointestinal tract. The smooth-muscle origin of the tumors was proved by light and electron microscopy and immunohistochemical staining for muscle-specific actin and desmin. Leiomyomata and leiomyosarcomata are rare tumors in childhood, suggesting a nonrandom association of tumors of smooth-muscle origin and the acquired immunodeficiency syndrome. We postulate that human immunodeficiency virus infection may play a direct or indirect role in tumor formation. (<i>JAMA</i>. 1990;263:3182-3184)
Psychosurgery
Authors: Jaan Kangilaski
Journal: JAMA (1974)

<h3>To the Editor.—</h3> <i>JAMA</i>MEDICAL NEWS does not exist to promote or defend the views of any individual, as suggested by Peter R. Breggin, MD, in his recent letter on psychosurgery (226:1121). The section's purpose is to present articles of current interest to physicians, and the articles to which he refers (225:913 and 225:1035) were intended to outline the kind of work done in psychosurgery, together with its political and social implications. Dr. Breggin claims that false statements were attributed to him in the articles. However, he has been quoted by other media as making substantially similar statements, and it is hard to believe there is a national conspiracy to misquote him. He was not, as he claims, the only critic of psychosurgery mentioned in the articles. The articles also state clearly (225:916) that the condition of Thomas R. and other psychosurgery patients has been described in conflicting terms by
Study seeks to learn best course of action for mothers-to-be with controlled PKU
Authors: K. Garrahan
Journal: JAMA (1987)

PREGNANCY in women with phynylketonuria (PKU) was rare before the 1980s because the retardation linked with this biochemical defect usually limited opportunities for dating or marriage. Now that early diagnostic testing and dietary measures enable many with the autosomal recessive trait to achieve normal IQ levels, these PKU patients lead relatively normal lives and are having children of their own. This prompts a new concern: high levels of phenylalanine in the blood of mothers with PKU may cross over the placenta in sufficient amounts to cause such defects as microcephaly, mental retardation, congenital heart disease, intrauterine growth retardation, or low birth weight (<i>N Engl J Med</i>1980;303:1202-1208). To cope with this problem, US and Canadian investigators in five centers are collaborating to develop a treatment program for women with PKU who want to have children. The National Institute of Child Health and Human Development, Bethesda, Md, is sponsoring the seven-year
Theoretical and Practical Considerations on the Problem of Metal. Metal Interaction
Authors: L. Magos, M. Webb
Journal: Environmental Health Perspectives (1978)

The interaction between two metals, which can be either synergistic or antagonistic, implies that the behavior of one is changed by the presence of the other.Possible mechanisms of these interactions, whkh include chemical association, competition for carriers, metabolic changes, induction of binding proteins, membrane alterations are discussed.
Request for Proposals (RFP)
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Request for Proposals (RFP) Get access JNCI: Journal of the National Cancer Institute, Volume 85, Issue 8, 21 April 1993, Page 682, https://doi.org/10.1093/jnci/85.8.682 Published: 21 April 1993
TT Virus
Authors: PETER A. L. BONIS
Journal: Journal of the American Society of Nephrology (1999)

Abstract. TT virus (TTV) is a newly described DNA virus that was first detected in the blood of three patients with elevated serum aminotransferases following transfusion who tested negatively for all known hepatitis viruses. The virus has been found worldwide with a high prevalence in the general population. However, accumulating evidence suggests that the virus is not a significant cause of acute or chronic liver disease. No other disease associations with infection have been described.
Contents, Vol. 57, No. 4, 1992
Authors: Paul R.J. Falger, Wybrand Op den Velde, Johannes E. Hovens, Erik G.W. Schouten, Johannes H.M. De Groen, Hans Van Duijn, Piet R. Wiepkema, Willem G.P. Schouten, William Yule, Wolter S. De Loos, Wybrand Op den Velde, Francine Albach, Walter Everaerd, Dora Black, Jean Harris-Hendriks, Tony Kaplan, Marc De Boer, Wybrand Op den Velde, Paul J.R. Falger, Johannes E. Hovens, Johannes H.M. De Groen, Hans Van Duijn, Johannes E. Hovens, Wybrand Op den Velde, Paul R.J. Falger, Eric G.W. Schouten, Johannes H.M. De Groen, Hans Van Duijn, Jacob D. Lindy, Bonnie L. Green, Mary Grace, Tom Lundin, Ulf Otto
Journal: Psychotherapy and Psychosomatics (1992)
Abstract 3048: Targeting protein deglycosylation as a newly identified vulnerable point in melanoma
Authors: Victor J.T. Lin, Ashwini Zolekar, Nigam M. Mishra, Yin Ying Ho, Hamed S. Hayatshahi, Abhishek Parab, Rohit Sampat, Xiaoyan Liao, Peter Hoffmann, Jin Liu, Kyle A. Emmitte, Yu-Chieh Wang
Journal: Cancer Research (2019)

Abstract As an enzyme that removes N-glycans from glycopeptides, N-glycanase 1 (NGLY1) deglycosylates denatured glycoproteins and allows proteasome-mediated protein degradation to efficiently occur. Although NGLY1 is known for this pivotal function, information regarding the responses of human cancer and normal cells to NGLY1 suppression is limited. Here, we examined how NGLY1 expression affects viability, tumor growth, and responses to therapeutic agents in melanoma cells and an animal model. Molecular mechanisms contributing to NGLY1 suppression-induced anticancer responses were revealed by systems biology and chemical biology studies. Using computational and medicinal chemistry-assisted approaches, we established novel NGLY1-inhibitory small molecules. Compared with normal cells, NGLY1 was upregulated in melanoma cell lines and patient tumors. NGLY1 knockdown caused melanoma cell death and tumor growth retardation. Targeting NGLY1 induced pleiotropic responses, predominantly stress signaling-associated apoptosis and cytokine surges, which synergize with the anti-melanoma activity of chemotherapy and targeted therapy agents. Pharmacological and molecular biology tools that inactivate NGLY1 elicited highly similar responses in melanoma cells. Unlike normal cells, melanoma cells presented distinct responses and high vulnerability to NGLY1 suppression. Our work demonstrated the significance of NGLY1 in melanoma cells, provided mechanistic insights into how NGLY1 inactivation leads to eradication of melanoma with limited impact on normal cells, and suggested that targeting NGLY1 represents a novel anti-melanoma strategy with the opportunity for a broad therapeutic window. Citation Format: Victor J.T. Lin, Ashwini Zolekar, Nigam M. Mishra, Yin Ying Ho, Hamed S. Hayatshahi, Abhishek Parab, Rohit Sampat, Xiaoyan Liao, Peter Hoffmann, Jin Liu, Kyle A. Emmitte, Yu-Chieh Wang. Targeting protein deglycosylation as a newly identified vulnerable point in melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3048.
Précis de Parasitologie.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Military Surgery.
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Non-surgical treatment for localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma: Preliminary results of a multicenter prospective study in Japan
Authors: K. Mera, A. Ohtsu, S. Nakamura, T. Yoshino, T. Nakamura, T. Sugiyama, I. Oda, T. Doi, S. Yamamoto, S. Ishikura
Journal: Journal of Clinical Oncology (2004)

6559 Background: Although eradication of Helicobacter pylori (HP) and radiation therapy (RT) have curative potential for gastric MALT lymphoma (G-MALT), no prospective study has yet been reported. This prospective study evaluated the efficacy and safety of this non-surgical treatment for localized G-MALT. The primary endpoint was failure-free survival (FFS). Methods: Eligibility criteria were histologically proven G-MALT, stage I–II1 (modified Ann-Arbor classification), age 20–75 years, PS 0–1, no prior therapy, adequate organ function, and written informed consent. Patients received HP eradication therapy (ET) consisting of a PPI-based triple regimen, and RT of 30 Gy in cases of residual or recurrent disease after ET. Results: Between 01/2001 and 12/2003, 149 patients were registered and 141 were included in the preliminary analysis. Of these, 16 (11%) were ineligible: 14 by central pathological review and two for other reasons. Baseline characteristics of the 125 eligible patients were: median age of 60 (35–75); male/female = 48/77; stage I/II1 = 120/5; HP +/–, 103/22; depth of invasion within/beyond the submucosa, 112/13. ET was administered completely to all patients. Twenty-five patients (20%) underwent RT due to persistent or recurrent disease after ET and 22 (88%) of these achieved complete remission with RT. No serious adverse events, such as hemorrhage or perforation of the stomach, were observed. With a median follow-up of 21.5 months, five events were considered "treatment failures": death not related to the treatment, 1; salvage gastrectomy, 1; transformation to diffuse large B-cell lymphoma, 2; and development to stage IV, 1. Two-year FFS and overall survival were 97.0%, and 99.2%, respectively. Conclusion: This organ-preserving treatment for localized G-MALT is safe and effective. It has the potential to become the standard treatment for this disease, although long-term follow up is necessary. This study was supported by a Grant-in-Aid (14–9) from the Ministry of Health, Labour, and Welfare, Japan. No significant financial relationships to disclose.